Some experts assume that since DYRK1A expression is ubiquitous, DYRK1A inhibitor therapy for diabetes will require conjugation of a DYRK1A inhibitor to a beta cell-specific targeting molecule. This evidence concerns the gene DYRK1A and diabetes mellitus.